Posts Tagged 'Palatin'

Shares in the penny stock of  Palatin Technologies Inc. (NYSE Amex: PTN) is now covered by analysts at Roth Capital with a “buy” rating. Palatin, a biopharmaceutical company dedicated to developing targeted, receptor-specific peptide therapeutics, has seen a significant drop in revenues compared to 2010 but could be looking at a rebound in the short-term.

Six weeks ago, Palatin announced that over 400 premenopausal women, diagnosed with female ...